MediWound Ltd. (MDWD) Stock Rating Reaffirmed by Oppenheimer Holdings, Inc.
Oppenheimer Holdings, Inc. reiterated their buy rating on shares of MediWound Ltd. (NASDAQ:MDWD) in a research report released on Monday. They currently have a $10.00 price target on the biopharmaceutical company’s stock. Oppenheimer Holdings also issued estimates for MediWound’s Q1 2018 earnings at ($0.11) EPS, Q2 2018 earnings at ($0.15) EPS, Q3 2018 earnings at ($0.12) EPS and Q4 2018 earnings at ($0.10) EPS.
A number of other analysts have also commented on MDWD. Aegis reaffirmed a buy rating and issued a $11.00 price target on shares of MediWound in a research note on Thursday, May 25th. SunTrust Banks, Inc. reaffirmed a buy rating on shares of MediWound in a research note on Monday, June 26th. Zacks Investment Research lowered MediWound from a hold rating to a sell rating in a research note on Tuesday, July 11th. Finally, Jefferies Group LLC set a $10.00 price target on MediWound and gave the stock a buy rating in a research note on Friday, August 25th. One equities research analyst has rated the stock with a sell rating and four have assigned a buy rating to the stock. The company has a consensus rating of Buy and a consensus target price of $9.19.
Shares of MediWound (MDWD) opened at 5.00 on Monday. MediWound has a 1-year low of $4.25 and a 1-year high of $8.58. The stock has a 50 day moving average of $6.30 and a 200 day moving average of $6.53. The company’s market cap is $109.77 million.
MediWound (NASDAQ:MDWD) last released its quarterly earnings data on Thursday, August 3rd. The biopharmaceutical company reported ($0.20) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.19) by ($0.01). The company had revenue of $0.69 million for the quarter, compared to analysts’ expectations of $0.69 million. MediWound had a negative net margin of 752.78% and a negative return on equity of 326.32%. The business’s revenue for the quarter was up 93.8% compared to the same quarter last year. During the same period last year, the company posted ($0.34) EPS. Analysts predict that MediWound will post ($0.76) EPS for the current year.
COPYRIGHT VIOLATION NOTICE: This piece was first reported by Watch List News and is the sole property of of Watch List News. If you are viewing this piece on another site, it was illegally stolen and reposted in violation of U.S. & international trademark & copyright laws. The legal version of this piece can be viewed at https://www.watchlistnews.com/mediwound-ltd-mdwd-stock-rating-reaffirmed-by-oppenheimer-holdings-inc/1579613.html.
Hedge funds have recently made changes to their positions in the stock. Wells Fargo & Company MN lifted its stake in MediWound by 19.7% in the first quarter. Wells Fargo & Company MN now owns 53,241 shares of the biopharmaceutical company’s stock worth $351,000 after acquiring an additional 8,745 shares during the period. Renaissance Technologies LLC lifted its stake in MediWound by 1.7% in the first quarter. Renaissance Technologies LLC now owns 75,600 shares of the biopharmaceutical company’s stock worth $499,000 after acquiring an additional 1,300 shares during the period. Migdal Insurance & Financial Holdings Ltd. lifted its stake in MediWound by 20.3% in the second quarter. Migdal Insurance & Financial Holdings Ltd. now owns 2,028,112 shares of the biopharmaceutical company’s stock worth $13,791,000 after acquiring an additional 342,165 shares during the period. Finally, Wellington Management Group LLP lifted its stake in MediWound by 11.0% in the first quarter. Wellington Management Group LLP now owns 2,157,839 shares of the biopharmaceutical company’s stock worth $14,241,000 after acquiring an additional 213,745 shares during the period. 23.47% of the stock is owned by institutional investors.
MediWound Ltd. is a biopharmaceutical company. The Company focuses on developing, manufacturing and commercializing therapeutics products in the fields of severe burns, chronic and other hard-to-heal wounds, connective tissue disorders and other indications. The Company’s product, NexoBrid, is indicated for the removal of dead or damaged tissue, known as eschar, in adults with deep partial- and full-thickness thermal burns, also referred to as severe burns.
Receive News & Ratings for MediWound Ltd. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MediWound Ltd. and related companies with Analyst Ratings Network's FREE daily email newsletter.